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Abstract  
An order-to-disorder structural switch activates the FoxM1 transcription factor 
Caileen M. Brison 
Intrinsically disordered transcription factor transactivation domains (TADs) function 
through structural plasticity, adopting ordered conformations when bound to transcriptional co-
regulators.  Many transcription factors contain a negative regulatory domain (NRD) that 
suppresses recruitment of transcriptional machinery through autoregulation of the TAD. We 
report the solution structure of an autoinhibited NRD-TAD complex within FoxM1, a critical 
activator of mitotic gene expression. We observe that while both the FoxM1 NRD and TAD are 
primarily intrinsically disordered domains, they associate and adopt a structured conformation. 
We identify how Plk1 and Cdk kinases cooperate to phosphorylate FoxM1, which releases the 
TAD into a disordered conformation that then associates with the TAZ2 or KIX domains of the 
transcriptional co-activator CBP. Our results support a mechanism of FoxM1 regulation in which 
the TAD undergoes switching between disordered and different ordered structures. 
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Chapter 1 – FoxM1 transcriptional regulation and the cell cycle  
1.1. Introduction  
1.1.1. The cell cycle and cancer 
The cell cycle is a tightly coordinated and highly conserved process that ensures cell 
fidelity across organisms. The maintenance of the cell cycle is critical for the life of an 
organism and disruption of this cell cycle can prove fatal. During development, cells are 
consistently dividing and differentiating. Once cells become terminally differentiated, they are 
no longer cycling. If cells acquire cancerous mutagens, the cell cycle can be reactivated in a 
manner that is deregulated and the subsequent consequence is tumorigenesis and cancer. 
Thusly, understanding the cell cycle is crucial not only for developmental biology, but cancer 
biology as well. 
The cell cycle can be thought of in four primary phases that are separated by distinct 
transitions. The cell cycle consists of two growth phases (G1 and G2) – or gap phases – that 
separate a mitotic phase (M) and a DNA synthesis phase (S).  In addition to cells undergoing 
cell division via the mitotic process, cells can also temporarily exit the cell cycle and go into a 
state of quiescence (G0) whereby the cells are no longer cycling. 
The deregulation of proper cell cycle is a hallmark of cancer biology and 
understanding the regulation of the cell cycle is not only critical for developmental biology but 
cancer biology as well. The role of cell cycle proteins in cancer biology and as potential 
cancer targets has been demonstrated by numerous studies and reviewed at length (Otto 
and Sicinski 2017; Hanahan and Weinberg 2000). The proper progression of the cell cycle is 
regulated in large part by transcription factors that coordinate the expression of cell cycle 
genes and ensure fidelity across the transitions between cell cycle phases. One of the key 
transitions in late stage cell cycle in the G2/M transition. The G2/M transition is critical as the 
passage of the transition prepares the cell for irreversible division. 
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1.1.2. The G2/M transition 
The G2/M transition is initiated by Cdk/cyclin complexes early in G1 stage and the 
core mechanism is conserved from yeast to humans (Swaffer et al. 2016; Murakami et al. 
2010; Pines 1995; Toyoshima et al. 1998). The phosphorylation of Cdk1/cyclin b by Cyclin-
dependent kinases (Cdks), Plk (Polo-like kinase), and Ckd-activating kinase (CAK) in 
humans helps drive the mitotic cell cycle. In contrast to these activating phosphorylation 
marks, the G2/M transition is inhibited by phosphorylation as Wee1 and Myt1 phosphorylation 
activity on Cdk/cyclin complexes hault cell cycle progression (Fesquet et al. 1993, 161; Poon 
et al. 1993; Murakami et al. 2010; Golsteyn et al., n.d.). Counteracting dephosphorylation on 
Cdk/cyclin complexes by CDC25 ensures proper temporal regulation of Cdk/cyclin 
phosphorylation and thusly cell cycle progression (Russell and Nurse 1986, 25; Sanchez et 
al. 1997, 25). 
The G2/M transition is also marked by an increase in late cell cycle genes and their 
subsequent activity, of note the heightened expression of Forkhead Box M1 (FoxM1) (Müller 
et al. 2016). In addition to kinase activity, gene expression patterns and transcriptional activity 
tightly regulate the G2/M transition. FoxM1 expression begins to rise as the cell cycle 
progresses from the G1 phase to the G2/M transition. This increase in FoxM1 levels and 
activity is concurrent with an overall increase in late cell cycle genes which is a direct 
consequence of early cell cycle regulation by the aforesaid (X. Chen et al. 2013, 1; Jamila 
Laoukili et al. 2005, 1; Wonsey and Follettie 2005, 1; Müller et al. 2016; X. Chen et al. 2013). 
This temporal regulation via phosphorylation is critical for cell cycle fidelity and the role of 
phosphorylation on FoxM1 will be detailed in this work. 
 
1.1.3 The role of FoxM1 in the cell cycle 
The passage of the G2/M transition is coordinated by cell cycle genes under the 
control of E2F, CDE, and CHR promoters as well as forkhead box (FOX) transcription factors 
which bind to a conserved FKH motif and are also recruited to CHR promoters (Müller et al. 
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2016; X. Chen et al. 2013). There are approximately 50 FOX proteins in the human genome 
that are categorized as such due to conservation of their winged helix DNA binding domain 
(Jackson et al. 2010). Of interest to the G2/M transition is the transcription factor Forkhead 
Box M1 (FoxM1) which controls cell cycle genes and is required for proper development, 
mitotic entry, and proper execution of the mitotic program (W Korver, Roose, and Clevers 
1997; Wouter Korver et al. 1998; Jamila Laoukili et al. 2005; I.-C. Wang et al. 2005; Wonsey 
and Follettie 2005). Throughout the cell cycle and leading towards full activation of FoxM1 we 
see a rise in Cyclin-dependent kinase (Cdk) activity beginning in G1 (J. Laoukili et al. 2008; 
Anders et al. 2011; Lüscher-Firzlaff, Lilischkis, and Lüscher 2006). This Cdk activity is critical 
for FoxM1 as we will discuss in detail. The activity of Cdks across the G1/S transition is 
subsequently followed by expression of FoxM1 and Polo-like kinase 1 (Plk1) as we progress 
towards G2 (Fu et al. 2008). The levels of FoxM1 and Plk1 peak across the G2/M transition 
and this coordinated expression aids in the passage of the G2/M transition and marks 
complete activation of FoxM1 and the expression of the FoxM1 genes in the mitotic program 
(J. Laoukili et al. 2008, 2) (Figure 1.1). FoxM1 expression is typically confined to dividing cells 
and is required for embryogenesis, hematopoiesis, and tissue repair (Wouter Korver et al. 
1998; Ramakrishna et al. 2007; Ustiyan et al. 2009). FoxM1 is essential for proper 
development; null mice exhibit an embryonic lethal phenotype due to liver, blood, heart, and 
lung abnormalities resulting from proliferation defects (Ramakrishna et al. 2007).  
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Figure 1.1: FoxM1 is a key regulator of the G2/M transition in the cell cycle. The cell 
cycle consists of the four primary phases; growth phase 1 (G1), growth phase 2 (G2), mitosis 
(M), and DNA synthesis (S). Cells can also exit the cell cycle and go into a state of non -
cycling (G0). Cdk expression levels begin to rise across the G1/S transition and we begin to 
see presumably inactive FoxM1 expression. As FoxM1 levels rise, Plk1 levels rise in a 
positive feedback loop, further phosphorylating FoxM1 with peak levels of fully 
phosphorylated FoxM1 across the G2/M transition.  
 
Alongside FoxM1’s critical role in cell cycle biology and development, we see FoxM1 
activity deregulated in all well characterized and studied cancers (Koo, Muir, and Lam 2012; 
Millour et al. 2010; Myatt and Lam 2007). FoxM1 misregulation at both the transcriptional and 
protein level has been observed in adenocarcinomas, breast cancer, squamous cell 
carcinomas, leukemia, lymphoma, and many additional malignancies (Kwok et al. 2010; 
Millour et al. 2010; Hyun Jung Park et al. 2011; Ramakrishna et al. 2007). Several studies 
have shown that FoxM1 activates tumor metastasis, mediates drug resistance, and regulates 
pluripotency-associated genes responsible for maintaining tumor cells in their undifferentiated 
state (Carr et al. 2010; Kwok et al. 2010; Z. Wang et al. 2011; Hyun Jung Park et al. 2011). 
Additionally, deletion of FoxM1 in cancer cells inhibits tumor development and growth and 
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leads to increased apoptosis (Kalinichenko et al. 2004; Wonsey and Follettie 2005). Due to 
the relevance of FoxM1 in proper development and the deregulation of FoxM1 in cancer 
cells, understanding the mechanism of activation and repression is crucial for cell cycle 
biology. In addition, detailing a structural and mechanistic profile of FoxM1 could also provide 
a platform for cancer specific biomolecular drug targets.  
 
1.1.4. FoxM1 is comprised primarily of intrinsic disorder 
FoxM1 – as well as many eukaryotic transcription factors – are comprised primarily of 
intrinsically disordered regions (Liu et al. 2006; Babu et al. 2011). Intrinsically disordered 
proteins (IDPs) or intrinsically disordered regions (IDRs) have become widely recognized as 
critical regulatory mechanisms of biological processes, specifically eukaryotic transcription 
and cellular signaling. Common mechanisms of transcriptional control by IDRs and IDPs is 
often a “folding upon binding” significant structural rearrangement and/or a small disordered 
region terminal to a globular domain gaining structure upon binding. A common and relevant 
example of these mechanisms is the folding of disordered TADs upon binding to CBP 
domains. (Xu et al. 2015; Ebert et al. 2008; Goto et al. 2002; F. Wang et al. 2012)These 
regions of intrinsic disorder give rise to the function of these transcription factors and allows 
for plasticity in structure (Minezaki et al. 2006; Dyson and Wright 2005). Eukaryotic 
transcription factors have been well characterized to have large regions of disorder that adopt 
order upon binding to partners (Wright and Dyson 2015; Liu et al. 2006). These regulatory 
mechanism gives rise to the ability of transcription factors to fulfill complex biological roles 
that require flexibility in their binding capacities. As such, the investigations of eukaryotic 
transcription factors through the lens of disorder provides important insight regarding 
function. 
Outside of the winged-helix DNA binding domain, FoxM1 is expected to be primarily 
unstructured based on primary sequence analysis (Littler et al. 2010). Predictions for disorder 
for Forkhead Box proteins have been reported to be approximately 70% on average 
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(Minezaki et al. 2006). Due to the large presence of disorder within FoxM1 and it’s critical role 
in cell cycle biology, understanding the role of disorder in this transcription factor is critical for 
our understanding of function. The domain architecture of FoxM1 is defined by functional 
portions of the protein that have been shown to have critical relevance to the overall 
transcriptional properties of FoxM1, notable the N-terminal repressive domain and the 
transactivation domain. However, despite the relevance of these domains, very little is known 
of FoxM1s structural properties outside of the DNA binding domain. 
 
1.1.5. FoxM1 domain architecture  
FoxM1 has an N-terminal regulatory domain (NRD), a winged helix DNA binding 
domain (DBD), a region of high Cdk consensus sites called the ‘Cdk site region’ (CSR) and a 
transactivation domain. In functional assays to assess transcription, removal of the NRD 
leads to constitutively active FoxM1 as monitored by luciferase activity and has been 
proposed to inhibit FoxM1 activity by sequestration of the TAD (H J Park et al. 2008). The 
NRD has one Cdk phosphorylation site (J. Laoukili et al. 2008). The DBD has conserved 
winged-helix DNA binding motif. The DBD is the unifying domain across all Forkhead family 
proteins and is highly conserved and structured. The FoxM1 DBD domain has been 
crystallized in complex with a consensus Forkhead DNA motif (Littler et al. 2010). The CSR is 
a region in FoxM1 named so for a high frequency of Cdk phosphorylation sites (Anders et al. 
2011; Lüscher-Firzlaff, Lilischkis, and Lüscher 2006; Kalinichenko et al. 2004; Y.-J. Chen et 
al. 2009, 1). Previous literature has not identified the CSR as a unique domain of FoxM1, 
however we see it has unique functional significance as will be demonstrated throughout this 
dissertation. Previous literature referred to the FoxM1 TAD as all residues C-terminal of the 
DBD. Here we clarify that region into distinct functional domains and identify a minimal TAD. 
The TAD is the most C-terminal fragment of FoxM1 and this region has been determined to 
have transcriptional activity as a domain (Littler et al. 2010; Shi, Kroeger, and Morimoto 1995; 
Wierstra and Alves 2006). The TAD of FoxM1 contains four Plk1 phosphorylation sites. 
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Despite the characterization of the functionality of domains, outside of the DBD very little is 
known about FoxM1 structure or dynamics. 
 
Figure 1.2: FoxM1 domain architecture and phosphorylation sites. Human FoxM1b 
isoform is a 748 amino acid transcription factor. FoxM1 has an N-terminal repressive domain 
(NRD), a winged-helix DNA binding domain (DBD), a Cdk site region (CSR), and a 
transactivation domain (TAD). Cdk phosphorylation sites are noted with a plus (+) and Plk1 
phosphorylation sites are noted with an asterisk (*). Domain boundaries are noted below the 
architecture diagram.   
 
1.1.6. FoxM1 regulatory interactions with CBP 
Studies have proposed that FoxM1 NRD sequesters it’s own TAD thus limiting 
transcriptional activity (J. Laoukili et al. 2008; Wierstra and Alves 2006; H J Park et al. 2008). 
TAD sequestration via an NRD in a common mechanism of repression among transcription 
factors and is critical for proper transcriptional regulation (Kim et al. 1999; H J Park et al. 
2008; Wierstra and Alves 2006; Shi, Kroeger, and Morimoto 1995; Spengler and Brattain 
2006). In addition, data show that FoxM1 Co-IPs with transcriptional co-activator CREB-
binding protein (CBP) (Major, Lepe, and Costa 2004). CBP is a common co-activator and is 
widely implicated in transcriptional activation through it’s ability to modify chromatin (Ogryzko 
et al. 1996; Kasper et al. 2006). CBP also has been shown to interact with numerous 
eukaryotic transcription factors to modulate and enhance their transcriptional activity (Major, 
Lepe, and Costa 2004; Mujtaba et al. 2004; Ogryzko et al. 1996). CBP is a large multi domain 
protein that also contains multiple domains that help facilitate protein:protein interactions. The 
protein:protein interaction domains of CBP are critical as they can help provide specificity to 
an otherwise nonspecific transcription factor. This is proposed to be pertinent within FoxM1 in 
particular which has been shown to have a very nonspecific binding pattern to DNA within the 
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genome (Sanders et al. 2015; X. Chen et al. 2013). Thusly, CBP can act as a liaison between 
transcription factors and the general transcription machinery while also enhancing 
transcription factor specificity. Among these protein:protein interaction domains are the zinc 
finger binding domains, TAZ1, TAZ2 and ZZ, the KIX domain, the nuclear receptor like 
coactivator binding domain (NCBD) domain, and the bromodomain (BRD) domain (De 
Guzman et al. 2006; Goto et al. 2002; I. Radhakrishnan et al. 1997; Mujtaba et al. 2004; De 
Guzman et al. 2000, 1). Due to the association between CBP and FoxM1 in a cell cycle 
dependent manner and the proposed mechanism of specificity, understanding the 
mechanism of FoxM1 activation is critical for out understanding of cancer biology. 
 
1.1.7. FoxM1 is a substrate of Cyclin-dependent kinases and Polo-like kinase 1 
FoxM1 is also a highly modified transcription factor and is a substrate of numerous 
kinases, of note here are the Cyclin dependent kinase (Cdk) family and Polo-like-1 (Plk1) 
kinase (J. Laoukili et al. 2008; Fu et al. 2008; Joshi et al. 2013). FoxM1 has long been known 
as a Cdk substrate and indeed we see as we transition from S phase through the G2/M 
transition we see a coordinated rise in Cdk activity on FoxM1 as well as an increase in 
FoxM1 transcriptional activity (Major, Lepe, and Costa 2004; J. Laoukili et al. 2008; Anders et 
al. 2011; Lüscher-Firzlaff, Lilischkis, and Lüscher 2006). While most of the literature indicates 
the Cdk activity is the primary driver of FoxM1 activation, phospo-specific antibody 
immunoblots and luciferase data show that FoxM1 is indeed a substrate of Plk1 and that 
FoxM1 activity increases as Plk1 concentration is increased in a dose-dependent manner (Fu 
et al. 2008). These data taken together indicate that both Cdk and Plk1 play a critical role in 
FoxM1 activation, yet we still do not understand the exact mechanism by which these kinases 
lead to FoxM1 activity.  
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1.1.8. Conclusions  
FoxM1 is a key regulator of the cell cycle and a prominent oncogene across all well 
characterized cancers (W Korver, Roose, and Clevers 1997; Wouter Korver et al. 1998; 
Kalinichenko et al. 2004, 1; Carr et al. 2010; Raychaudhuri and Park 2011). Despite critical 
roles as both a transcription factor and oncogene very little is known about the mechanistic 
details of FoxM1. This is likely due to a high frequency of intrinsically disordered regions 
(IDRs) within FoxM1 and forkhead box proteins overall and the inherent challenge of working 
with IDRs in vitro (Minezaki et al. 2006). While FoxM1 has been targeted as a cancer 
therapeutic, the current targets are limited by a lack of detailed mechanism as well as off 
target effects as a consequence of targeting DNA binding ability (Gormally et al. 2014; S. K. 
Radhakrishnan et al. 2006). FoxM1 activity is directly associated with Cdk activity and Plk1 
activity and the subsequent phosphorylation state of FoxM1. This dissertation shows that Cdk 
and Plk1 play unique yet interdependent roles in the ultimate de-repression of FoxM1. This 
relief of repression highlights the plasticity of FoxM1 structure as FoxM1 navigate between 
alternative confirmations dependent on the associated binding partner. Investigating 
oncogenic eukaryotic transcription factors in the context of the cell cycle provides deep 
insight towards potential cancer targets. This dissertation aims to give context to the ways in 
which FoxM1 is regulated in a phosphorylation dependent manner. This work can be used to 
guide the design of cancer therapeutics that specifically target FoxM1. 
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Chapter 2: Phosphorylation of FoxM1 dictates association with regulatory partners 
2.1. Introduction 
Phosphorylation is a conserved mechanism of protein regulation and plays critical 
roles in timing and execution of the mitotic program (Swaffer et al. 2016; Barik et al. 2010; 
Alberts et al. 2002; Rhind and Russell 2012). The majority of data and hypotheses in the field 
of FoxM1 regulation indicate that Cdks are the primary driver of FoxM1 activation (Anders et 
al. 2011; Major, Lepe, and Costa 2004; J. Laoukili et al. 2008; Lüscher-Firzlaff, Lilischkis, and 
Lüscher 2006). While it is evident that Cdks play a crucial role in FoxM1 activation, 
understanding the mechanism by which Cdks activate FoxM1 is not explicitly known. FoxM1 
undergoes phosphorylation by Cdks beginning in the G1/S transition as we begin to see 
FoxM1 expression rise. As the cell cycle progresses, we see increasing levels of Cdk 
phosphorylated FoxM1 protein levels as well as FoxM1 transcriptional activity. Consequently, 
the role of Cdk is known to be critical for FoxM1 activity (Swaffer et al. 2016; Major, Lepe, 
and Costa 2004). 
In addition to the role of Cdks in FoxM1 activation, there is an increasing amount of 
data indicating that Plk1 may have a direct role in FoxM1 activity. As the cell cycle 
progresses across the G2/M transition we see increasing levels of FoxM1 phosphorylation by 
Plk1 (Fu et al. 2008). We also know that Plk1 is a bona fide FoxM1 target gene and the 
subsequent expression of Plk1 leads to the establishment of a positive feedback loop 
whereby Plk1 expression leads to increased FoxM1 activity (Jamila Laoukili et al. 2005; Fu et 
al. 2008). Plk1 has a conserved mechanism of phosphorylation that requires binding to Cdk 
phosphorylated residues and subsequent phosphorylation. Plk1 contains tandem polobox 
domain that bind to Cdk phosphorylated residues at polobox binding substrate sites that allow 
subsequent phosphorylation of an N-terminal kinase domain (Lee et al. 2014, 1). 
Subsequently, the coordination of Cdks and Plk1 activity likely plays a crucial role in the 
overall activation of FoxM1 throughout the cell cycle. This dissertation describes the detailed 
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mechanism by which both Cdks and Plk1 activate FoxM1 and coordinately drive 
transcriptional activation across the G2/M transition. 
 
2.2. Results 
2.2.1. FoxM1 NRD directly binds the TAD 
Performed by co-author of this study Dr. Aimee Marceau  
 To assess the model that FoxM1 NRD inhibits transcription by sequestration of the 
TAD we tested binding of FoxM1 domains in vitro. The FoxM1 NRD inhibits transcription 
factor transactivation activity early in the cell cycle. Transcription reporter assays suggest that 
the NRD negatively regulates the TAD through a sequestration mechanism (Park et al., 
2008b; Wierstra and Alves, 2006a). To confirm a direct interdomain association and to define 
more precisely the NRD and TAD domain boundaries, we purified recombinant protein 
constructs of various lengths and assayed their association in trans using isothermal titration 
calorimetry (ITC) (Figure 1.2). We first used an NRD-containing construct that includes the 
entire N-terminus of FoxM1 up until near the start of the DBD (residues 1-203 in human 
isoform FoxM1b) and a long C-terminal construct (residues 526-748) including the Cdk-site 
rich region (CSR) and putative TAD. We observe binding between these protein fragments 
and measured an affinity of Kd = 2 ± 1 µM (Figure 1B and 1C). Using sequence conservation 
we designed a minimal NRD (1-114) and minimal TAD (696-748) and found that they 
associate with comparable affinity (Kd = 3 ± 2 µM). When we attempted to shorten the 
constructs further, we found loss of affinity (Figure 2.1), so we conclude that these fragments 
contain the approximate sequences necessary and sufficient for interdomain association. 
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Figure 2.1: FoxM1 NRD directly binds TAD in vitro. (A) Isothermal titration calorimetry 
(ITC) data indicate association between purified TAD and NRD-containing constructs. (B) ITC 
affinity measurements for the indicated purified protein constructs. Domains are indicated as 
in Figure 1.2. 
 
 
2.2.2. FoxM1 directly binds to co-activator CBP 
 The requirement of Cdk phosphorylation for FoxM1 activity has been linked to FoxM1 
recruitment of the co-activator acetyltransferase proteins CBP and p300 (Major et al., 2004). 
These co-activators share high sequence homology and contain several protein-protein 
interaction domains that associate with transcription factor TADs (Wang et al., 2013). We 
tested three common TAD interaction domains in CBP and found that purified TAZ2 and KIX 
domains bind the FoxM1 TAD, while TAZ1 does not. The TAZ2 and KIX domains bind with 
0.7 ± 0.3 and 2.7 ± 0.5 µM affinity, respectively (Figure 2.2A). For future structural studies 
and binding assays, we focus on TAZ2 binding to TAD due to the higher affinity.  
 
2.2.3. FoxM1 TAD cannot simultaneously bind multiple domains of CBP 
 Previous literature has indicated that forkhead box protein TADs can contain multiple 
distinct binding regions within the functional TAD, and that these regions can bind discrete 
regions of CBP domains (Wang et al. 2012). This raises questions regarding a potential for 
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bimodal binding capacity of the TAD. More specifically, we aim to test the binding of the 
FoxM1 TAD – as defined in this study – and it’s potential to be truncated into sub-domains 
that bind CBP. Additionally, we aim to test the TADs ability or lack thereof to bind to multiple 
domains of CBP simultaneously. 
 We designed small TAD fragments based on conservation and assayed the ability of 
the fragments to bind to TAZ2. We see that neither the N-terminal fragment (694-726) nor the 
C-terminal fragment (727-748) can bind CBP-TAZ2, indicating that the FoxM1 TAD as 
defined in this study is the minimal functional TAD. In addition, when we competitively titrate 
CBP fragments into bound CBP-TAD complexes we see binding in a manner that seems to 
be dictated purely by affinity. To test the competitive binding for the TAD, we use ITC to 
assay for competition between CBP domains for TAD. Upon titration of TAD with KIX we see 
a binding affinity of approximately 3 µM. Subsequent titration of TAZ2 gives heats by ITC and 
an apparent Kd of approximately 2 µM. However, if we first saturate TAD with TAZ2 and 
assay for binding of KIX to TAD:TAZ2 complex we see no heats by ITC. This indicates that 
rather than a mechanism of bimodal binding, FoxM1 binds either KIX or TAZ2 in a manner 
dependent of affinity and cellular availability (Figure 2.2C). 
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Figure 2.2: FoxM1 binds CBP. (A) Raw ITC data and the calculated affinities of FoxM1 TAD 
(696-748) binding to the KIX, TAZ1, and TAZ2 domains of CBP. (B) CBP domain architecture 
highlighting the domains of interest; TAZ2 (pink), KIX (green), and TAZ1 (orange). (C) ITC 
affinities of the indicated FoxM1 construct for TAZ2 and CBP fragments in competition. *n = 
1. 
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2.2.4 CBP cannot bind auto-repressed FoxM1 
 We could not detect binding of the NRD-TAD fusion protein to the TAZ2 domain 
using ITC, and we observed weak association to an NRD-TAD complex using NMR (Figure 
2.3). The fusion protein containing the I88A interface mutation did bind in the ITC assay, 
albeit with slightly weaker affinity than the TAD alone (Figure 2.3A). These results support the 
model that the NRD inhibits FoxM1 activity by sequestering the TAD from interacting with 
transcriptional co-activators. 
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Figure 2.3: CBP cannot bind auto-repressed FoxM1. (A) Affinities of WT and I88A NRD-
TAD fusion for TAZ2. (B) NMR HSQC of 100 µM FoxM1 NRD-TAD fusion with excess TAZ2 
titrated in. Titration concentrations are indicated, 1 M equivalent and 5 M excess, 
respectively. 
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2.2.5. Cdk phosphorylation has no direct effect on NRD-TAD binding 
Performed by co-author of this study Dr. Aimee Marceau  
 In the current accepted model, Cdk phosphorylation relieves NRD inhibition by 
directly destabilizing the NRD-TAD association (Anders et al., 2011; Laoukili et al., 2008a; 
Park et al., 2008b; Wierstra and Alves, 2006b). We addressed with purified domains whether 
phosphorylation of Cdk sites in human FoxM1 directly affects the inhibitory NRD-TAD 
association. For these assays, we phosphorylated Cdk consensus sites using Cdk2-Cyclin A 
(Cdk2-CycA) as previously described (McGrath et al., 2017), we verified phosphorylation by 
electrospray mass spectrometry, and we measured affinities using the ITC assay. We first 
observed that phosphorylation of the NRD, which contains a single conserved consensus 
Cdk site (S4), has minimal effect on the affinity of the NRD for the CSR-TAD. While there are 
no consensus Cdk sites in the TAD, there are several sites in the Cdk site region (CSR). To 
test if Cdk phosphorylation of this region directly affects the NRD-TAD association, we 
generated protein constructs in which the CSR is included with the TAD or fused to the NRD. 
The CSR-TAD construct (amino acids 526-748) binds the NRD with similar affinity whether or 
not it is first phosphorylated with Cdk2-CycA (Figure 4A).  The NRD-CSR fusion protein 
(amino acids 1-114 + 526-674) binds the TAD with similar affinity as the NRD alone and with 
similar affinity whether or not it is first phosphorylated with Cdk2-CycA. These measurements 
are consistent with the lack of Cdk sites near the NRD-TAD interface in our structural model. 
The observation here that phosphorylation of Cdk consensus sites has no direct effect on the 
repressive NRD-TAD interaction suggests that Cdk phosphorylation is not sufficient for 
activation of the FoxM1 transcription factor (2.4A).      
 
 
2.2.6. Cdk phosphorylation has no effect on CBP binding to FoxM1 
Performed by co-author of this study Dr. Aimee Marceau  
 Cdk phosphorylation has long been assumed to be the primary driver of FoxM1 
activation (Major, Lepe, and Costa 2004; J. Laoukili et al. 2008; Lüscher-Firzlaff, Lilischkis, 
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and Lüscher 2006). Under the belief that FoxM1 activation is Cdk phosphorylation dependent 
you would expect that Cdk phosphorylation would play a role in changing the affinity between 
FoxM1 TAD and co activator CBP. We see no change in affinity upon Cdk phosphorylation 
between FoxM1 TAD-CSR and CBP TAZ2. Regardless of phosphorylation state we see an 
affinity of approximately 1.5 µM between CBP TAZ2 and FoxM1 TAD-CSR thus showing that 
Cdk phosphorylation plays no role in direct enhancement of association with co-activator 
(Figure 2.4B). 
 
Figure 2.4: Cdk phosphorylation has no direct role in regulation of FoxM1 interactions. 
(A) Purified and isolated domains of FoxM1 were titrated and affinities were determined by 
ITC. Phosphorylation states are indicated in the CSR and/or NRD. (B) Purified and isolated 
domains of CBP were assayed for binding to FoxM1 CSR-TAD and affinities were 
determined by ITC. Cdk phosphorylation sites are indicated in the CSR.  
 
2.2.7. Plk phosphorylation has no effect on CBP binding to FoxM1 
 In similar vain to Cdk phosphorylation of FoxM1, Plk1 activity has been shown to 
enhance transcriptional activity of FoxM1 in a dose dependent manner (Fu et al. 2008). 
Under the belief that FoxM1 activation is enhanced by Plk1 activity, you could expect Plk1 
phosphorylation of the FoxM1 TAD to enhance the binding to co-activator CBP. To test this, 
we phosphorylated the FoxM1 TAD by incubating with purified Plk1, and we confirmed 
quantitative phosphorylation of 4 sites (Ser702, Ser715, Ser724, and Ser741) with 
electrospray mass spectrometry. Upon phosphorylation of either the FoxM1 CSR-TAD or 
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TAD alone by Plk1 in vitro we see no significant change in affinity between a phosphorylated 
and unphosphorylated state (Plk1 data not shown). 
 
2.2.8. Plk1 phosphorylation obliterates NRD binding 
Performed by co-author of this study Dr. Aimee Marceau  
 Plk1 activity has also been implicated in FoxM1 activation (Fu et al., 2008). The 
FoxM1 TAD contains 5 potential serine Plk1 phosphorylation sites. We phosphorylated the 
FoxM1 TAD by incubating with purified Plk1, and we confirmed quantitative phosphorylation 
of 4 sites (Ser702, Ser715, Ser724, and Ser741) with electrospray mass spectrometry. These 
sites are all conserved (Figure 1.2), and two of them (Ser715 and Ser724) were previously 
identified as Plk1 sites in cells (Fu et al., 2008). We observed that the Plk1 phosphorylated-
TAD no longer binds the NRD by ITC (Figure 2.5). Using TAD constructs with serine to 
alanine mutations, which cannot be phosphorylated, we tested the importance of specifically 
phosphorylating Ser715 on the NRD-TAD affinity.  When the three other Plk1 sites are 
mutated, the phosphorylated TAD still lacks any detectable affinity for the NRD. In contrast, 
phosphorylation of a Ser715A construct results in no change in affinity.  We conclude that 
Ser715 phosphorylation by Plk1 is necessary and sufficient for inhibiting the NRD-TAD 
association. In addition, we see when U2OS cells are transfected with a TAD mutant that 
cannot be phosphorylated by Plk1 at site 715 (S715A) we see no enhancement of 
transcriptional activity. This contrasts with I88A NRD mutation which destabilizes the NRD-
TAD association in which we see enhancement of transcriptional activity. We see no 
significant change in transcriptional activation upon TAD mutant V708A/L709A that disrupts 
the NRD-TAD association likely to a disruption of co-activator recruitment. We test this 
hypothesis in Chapter 3. This indicates that the phosphorylation event is linked to de-
repression and when TAD cannot be phosphorylated at 715 the TAD cannot be de-
repressed. These results are consistent with and explain the previous report that an 
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Ser715A/Ser724A mutation decreases FoxM1 activation of several mitotic genes in U2OS 
cells (Fu et al., 2008). 
 
Figure 2.5: Phosphorylation of the TAD by Plk1 regulates NRD-TAD interactions.  (A) 
ITC binding affinity of NRD 1-203 for WT TAD and TAD containing mutations at Plk1 sites. 
Measurements were made with and without Plk1 phosphorylation. (B) Luciferase reporter 
expression from the 6DB promoter.  Only experiments in which significant differences in the 
relative luminescence between expression of FoxM1 alone (control, black) or co-expression 
with Plk1 (purple) are indicated with asterisks (* p < 0.05, using two-tailed student’s t-test). 
 
2.2.9. Cdk phosphorylation of the CSR allows Plk1 polobox binding domain association 
Performed by co-author of this study Dr. Aimee Marceau  
 Plk1 has tandem polobox binding domains that allow Plk1 to bind to phosphorylated 
Cdk substrates and allow for subsequent phosphorylation with an N-terminal kinase domain 
(Lee et al. 2014). This mechanism is conserved among the Polo-like kinase family from yeast 
to humans. FoxM1 has a polobox binding domain in the CSR, specifically residue 585. To 
test for an association between Plk1 polobox binding domain and CSR we purified isolated 
domains and tested for their binding by ITC. We see that unphosphorylated CSR does not 
bind the polobox domain of Plk1. Conversely, the Cdk phosphorylated CSR binds the 
polobox domain of Plk1 with nanomolar affinity (Figure 2.6). 
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Figure 2.6: Plk1 polobox binding domain binds Cdk phosphorylated CSR. Isolated and 
purified domains were assayed for binding by ITC. Affinities are reported below. No heat by 
ITC is no reported affinity.  
 
2.2.10. Conclusions  
 . This study details the narrative of FoxM1 activation through the lens of de-
repression of the NRD in a phosphorylation dependent manner. This study concludes that 
Cdk phosphorylation plays no direct role in relief of repression from the NRD, but rather that 
phosphorylation of the CSR by Cdk allows for Plk1 to bind and phosphorylate the C-terminal 
TAD. The phosphorylation of the TAD, specifically at S715, disallows sequestration of the 
TAD by the NRD and maintains binding capacity to transcriptional co-activator CBP. 
 
 
 
 
 
 
 27 
 
2.3. Discussion  
The idea that different phosphorylation events have specific and distinct roles is in 
contrast to several proposed models for multisite phosphorylation in the cell cycle, in which a 
threshold aggregate of redundant phosphorylation events drives a change in protein activity 
(Harvey et al., 2005; Kim and Ferrell, 2007; Nash et al., 2001). Our observation of specificity 
in the effects of FoxM1 phosphorylation more resembles what has been proposed for the 
retinoblastoma protein, in which specific phosphorylation events drive distinct structural 
changes or protein-protein interactions (Rubin, 2013). While Cdks and Plk1 have been or are 
cancer therapeutic targets, this can provide more insight into targeting the FoxM1 pathway for 
cancer. This work clarifies the role of Cdks and Plk1 and can help guide more targeted 
cancer kinase therapeutics acting upstream of FoxM1. 
 
2.4. Materials and Methods 
Protein Expression  
The human FoxM1 constructs (1-114, 1-203, 1-332, 80-114, 1-117/694-748 fusion, 1-
117/694-748 fusion ∆25-50, 1-114/526-674 fusion, 573-635, 526-748, and 696-748) were 
expressed in and purified from E. coli as N-terminal GST fusion proteins with TEV cleavage 
sites. Cells were induced in mid-log phase with 1 mM IPTG, cells were grown for 3-4 hours at 
25 °C. All proteins were purified from lysates with glutathione sepharose affinity 
chromatography. Fusion and C-terminal (TAD) constructs were further purified with Q-
sepharose and then cleaved with TEV protease. Proteins were buffer exchanged into 25 mM 
Tris, 1 M NaCl, 5 mM DTT (pH 8.0) and then passed over glutathione sepharose resin to 
remove free GST, concentrated, and run over Superdex-75 (GE Healthcare) into 20 mM 
HEPES pH 7.5, 150 mM NaCl, 5% glycerol. After TEV cleavage, N-terminal (NRD) constructs 
were diluted in 20 mM Hepes, 5 mM DTT (pH 7.0), and purified with S-sepharose and 
Superdex-75 as described for C-terminal constructs.  
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Human Plk1 kinase domain (13-345) was expressed with an N-terminal His tag in Sf9 
cells using the FastBac expression system. Cells were harvested and lysed in a buffer 
containing 50 mM Tris, 300 mM KCl, 2 mM MgCl2, 10 mM Imidazole (pH 8.0), Sigma 
Protease Inhibitor (P8340) and 2mM phenylmethylsulfonyl fluoride. Protein was purified with 
Nickel Sepharose Excel resin (GE Healthcare) equilibrated in lysis buffer. The resin was 
washed with a buffer containing 1 M KCl, 50 mM Tris, 40 mM Imidazole, 10 mM BME, 2 mM 
MgCl2 (pH 8.0) and protein was eluted in 200 mM KCl, 50 mM Tris, 300 mM Imidazole, 10 % 
glycerol v/v, 10 mM BME, 2 mM MgCl2 (pH 8.0). Protein was dialyzed into storage buffer (200 
mM KCl, 50 mM Tris 8, 10 mM BME, 2 mM MgCl2, 10% glycerol v/v, (pH 8.0)) and stored at -
80˚C. The polobox domain of human Plk1 and Cdk2-CycA were expressed and purified as 
previously described (Cheng et al., 2003; McGrath et al., 2013). 
 
Mus musculus CBP KIX (CBP residues 567-653), TAZ2 (residues 1764-1855) and 
TAZ1 (residues 340-439) were expressed in E. coli.  KIX was expressed with a His tag and 
first purified using nickel sepharose affinity chromatography as described above.  TAZ2 was 
expressed as an MBP fusion protein and purified using amylose sepharose affinity 
chromatography and S-sepharose ion exchange chromatography.  The TAZ2 contained 
cysteine to alanine point mutations (C1776A, C1784A, C1827A, C1828A) that increase 
solubility and stability (De Guzman et al., 2000). ZnSO4 was kept in growth media for TAZ2 
growth at a concentration of 1 µM. TAZ1 was expressed with a His-Nus-XL affinity tag and 
purified using nickel affinity resin followed by tag cleavage. All CBP domains were further 
purified with Superdex 75 size exclusion chromatography.  
 
  
Isothermal titration calorimetry  
 Equilibrium dissociation constants for FoxM1 NRD constructs binding to TAD 
constructs were obtained using ITC with a MicroCal VP-ITC system. FoxM1 protein 
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fragments were run over Superdex-75 (GE Healthcare) into 20 mM HEPES pH 7.5, 150 mM 
NaCl, 5% glycerol. TAD fragments (100-500 µM) were titrated into the NRD fragments (10-50 
µM) at 25°C. The equilibrium dissociation constant for FoxM1 CSR binding to the Plk1 
polobox domain was similarly determined. CSR (300 µM), either phosphorylated or 
unphosphorylated with Cdk2-CycA, was titrated into polobox (30 µM) at 25°C. Reported Kd 
values are the average fits from two or three technical replicates with the standard deviation 
reported as error. For data fitting in experiments involving the FoxM1 NRD, we adjusted NRD 
concentration such that the stoichiometry was close to 1. We chose this approach for the 
fitting, because we otherwise noticed variability in the n value that we attribute to difficulty 
measuring the NRD concentration from its low extinction coefficient. If no significant heat was 
detected above background, we conclude no association. In the case of titrating the TAD 
fragment 694-726 into 1-203, we observed small heats but could not fit the data, so we 
conclude the affinity must be weaker than 10 µM. 
 Equilibrium dissociation constants for CBP domain binding to FoxM1 TAD were 
obtained using ITC with Micro Cal VP-ITC system. Both FoxM1 and CBP proteins were run 
over Superdex-75 (GE Healthcare) into 20 mM HEPES 7.5, 150 mM NaCl, 5% glycerol v/v. 
CBP-TAZ2 (250-350 µM) was titrated into FoxM1 TAD (20 – 40 µM) at 25ºC. Because of the 
difficulty in determining CBP-TAZ2 concentrations, the concentrations were adjusted to a 
stoichiometry of 1.0. CBP-KIX (600 μM) was titrated into FoxM1 TAD (60 μM) at 30˚C in the 
same buffer. Reported Kd values are the average fits from two or three technical replicates 
with the standard deviation reported as error.   
 
Kinase reactions 
FoxM1 protein constructs following final purification were incubated with 10 mM ATP, 
50 mM MgCl2, and 10% by mass of either Plk1 kinase domain, Cdk2-CycA, or both Plk1 and 
Cdk2-CycA, overnight at 4 °C. Phosphorylation of the protein was confirmed by electrospray 
mass spectrometry using a Sciex X500B QTOF system. 
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Cell culture  
Human osteosarcoma U2OS cells were maintained in Dulbecco’s modiﬁed Eagle’s 
medium (DMEM) containing 10% fetal bovine serum, 2mM L-glutamine, and 1x Penicillin 
Streptomycin and split every 2-3 days. Cells tested negative for Mycoplasma contamination 
using a PCR assay. 
Reporter assays were performed using the FoxM1c isoform, which includes 15 amino 
acids downstream of the DNA binding domain that are absent in FoxM1b. The amino acid 
sequence of the NRD, CSR and TAD domains are identical in FoxM1c and FoxM1b. For 
clarity, mutations are indicated using FoxM1b numbering throughout the figures and text. 
Mutants were expressed from the pCDNA3 plasmid with and contain an N-terminal FLAG 
tag: pCDNA3-FOXM1C (WT), pCDNA3-FOXM1C-I88A, pCDNA3-FOXM1C-S715A, 
pCDNA3-FOXM1C-V708A, L709A. The day prior to transient transfections, 2x105 U2OS cells 
were seeded into 12-well plates in antibiotic-free medium (DMEM/ 10%FBS/L-glutamine). 
Cells were then transfected with Lipofectamine 2000 Reagent (Invitrogen 11668-019) 
according to the manufacturer’s protocol with 650ng pGL3-6DB-reporter. Cell lysates were 
prepared 25 hours post-transfection using the Promega Dual Luciferase Reporter Assay 
System kit (Promega, E1960) and luminescence was measured on a Promega Glo Max. 
Relative luminescence was determined by normalizing the Firefly luciferase activity 
(expressed by pGL3 reporter plasmids) activity to Renilla Luciferase (transfection efficiency 
control). Three technical replicate transfections were performed in each experiment and each 
experiment was carried out three times (biological replicates). Analysis was performed in 
Excel and GraphPad Prism software.   
 
NMR Sample prep 
NMR experiments for resonance assignment were performed on a Bruker Avance III 
HD 800-MHz spectrometer equipped with a cryogenically cooled probe head.  All samples 
were prepared in a buffer containing 20 mM sodium phosphate pH 6.3, 100 mM KCl, and 5% 
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(v/v) D2O. Dr FoxM1 NRD-TAD apo spectra was acquired at 100 µM and 1 M equivalent 
unlabeled CBP-TAZ2 was titrated in. In a separate NMR tube, 100 µM Dr FoxM1 NRD-TAD 
and 5 M excess CBP-TAZ2 spectra was acquired to compensate for changes in volume upon 
titration. Data was processed with NMRPipe and analyzed with CCPNmr (Vranken et al. 
2005; Delaglio et al. 1995).  
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Chapter 3: FoxM1 structural confirmations and dynamics  
 
3.1 Introduction  
 
Structural plasticity and dynamics are a highly conserved mechanism of regulation 
across eukaryotic transcription factors (Minezaki et al. 2006; Liu et al. 2006; Bah et al. 2015). 
We understand that transcription factors will often fold into secondary structure upon binding 
to partners and we see this mechanism commonly among transcription factors that bind to 
CBP (F. Wang et al. 2012; Mujtaba et al. 2004; Goto et al. 2002). An excellent example of 
this regulation is the hormone receptor activator ACTR bound to CBP domain NCBD. Upon 
binding to CBP the ACTR gains α-helical structure from a disordered state. In addition, the 
NCBD transitions from a globule state with helical propensity to an α-helical structure (Ebert 
et al. 2008). We see this pattern of folding upon binding across many transcription factors 
and this work details the mechanism by which FoxM1 undergoes similar regulation.  
While auto-regulatory repressive domains are common among transcription factors, 
there is very little mechanistic or structural insight on how auto-repression via transcription 
factors is regulated. This is likely due to the physical challenges of working with intrinsically 
disordered regions of transcription factors. Here we show through NMR and Rosetta 
modeling that the FoxM1 NRD-TAD auto-repressed complex forms a hydrophobic core. 
Alongside our structural model we highlight the importance of residues in that core for 
transcriptional regulation. Lastly, we show that FoxM1 undergoes distinct structural 
rearrangements dependent on binding association. 
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3.2. Results  
3.2.1. The FoxM1 TAD has intrinsic disorder and partially globular domains 
Performed in collaboration with co-author of this study Dr. Aimee Marceau  
Outside of the winged helix DNA binding domain, FoxM1 is predicted to be primarily 
disordered outside highly conserved region of the TAD and NRD. While there has been a 
long-established belief that structure leads to function, the scientific community is beginning 
to understand the limits of structure and function. More specifically, the community of 
structural biologists is beginning to realize the importance of disorder in protein structure and 
function. The forkhead box family of proteins is predicted to be approximately 70% disordered 
as predicted by DISOPRED2 (Minezaki et al. 2006). Outside of the winged helix DNA binding 
domain, there remains no structural characterization of FoxM1 as a consequence (Littler et 
al. 2010). Sequence prediction software programs predict that FoxM1 could present small 
regions of structure within the NRD and the TAD, but due to the inherent plasticity of these 
domains no structures have been solved. FoxM1 is thusly characterized primarily as a 
transcription factor with high frequency of intrinsically disordered regions. 
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Figure 3.1: FoxM1 NRD and TAD are intrinsically disordered. NMR HSQC of both the apo 
NRD (left) and TAD (right) are shown above the domain architecture of full length human 
FoxM1. Both NRD and TAD show spectra with chemical shifts consolidated around 8.5 to 7.5 
for amide proton, indicative of disorder. 
 
3.2.2. FoxM1 NRD-TAD structural model  
 
1. Performed by co-author of this study Dr. Aimee Marceau in collaboration with 
Santrupti Nerli, Dr. Nikolaos Sgourakis, and Dr. Andrew McShan 
 
We combined NMR with Rosetta structural modeling to understand how the FoxM1 
NRD binds the TAD in the autoinhibited conformation (Nerli and Sgourakis 2019). NMR 
studies of TAD-coactivator complexes have primarily utilized an approach in which the two 
domains are purified separately with isotope labeling of only one protein (De Guzman et al. 
2006; I. Radhakrishnan et al. 1997; Zor et al. 2004). We found that spectra of the human 
NRD-TAD complex assembled from independently purified domains were generally of poor 
quality. We alternatively purified a protein construct for structural studies in which the minimal 
NRD and TAD were fused by a short cleavable linker (1-117/694-748). This fusion protein 
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does not bind additional TAD in trans, which suggests that the TAD and NRD are associated 
within the fusion.  
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Figure 3.2: Solution structure of an NRD-TAD complex. (A) Sequence alignment of FoxM1 orthologs 
from Homo sapiens (human), Mus musculus (mouse), Gallus gallus (chicken), Xenopus laevis (frog), 
and Danio rerio (zebrafish). Conserved residues in at least four of the five sequences are colored. 
Secondary structure assignments are determined from dictionary of protein secondary structure (DSSP) 
analysis of the final NMR ensemble (Kabsch and Sander, 1983). Dashed lines indicate residues that are 
present in the NMR construct but are not included in the structure calculations and are significantly 
disordered according to the backbone chemical shifts.  The asterisks (*) mark residues for which 
interdomain (NRD-TAD) NOEs have been unambiguously assigned. The carets (^) mark poorly 
conserved sequence insertions not shown in the frog sequence. Plk1 phosphorylation sites in the TAD 
are boxed. (B) Secondary Structure Index (SSI) derived from TALOS-N analysis of backbone chemical 
shifts corresponding to residues in the NRD (cyan) and TAD (pink) domains. Positive SSI values are 
consistent with β-strand and negative values are consistent with α-helical structure. Amino acid 
numbering corresponding to the human sequence is used. (C) Estimated backbone order parameters 
(Random Coil Index RCI-S2) derived from the chemical shifts are shown for residues in the NRD and 
TAD (Berjanskii and Wishart, 2005). Lower RCI-S2 values indicate flexibility, higher RCI-S2 values 
indicate rigidity. (D) Overlay of ten final Rosetta models guided by the chemical shift, NOE, and RDC 
data. (E) Topology diagram of the NRD and TAD domains. (F) Structure of the five-stranded β-sheet. 
Unambiguously assigned interstrand amide proton-proton NOEs are shown as lines. 
 39 
 
We observed optimal NMR spectra using the protein sequence from zebrafish, 
deleting an internal loop in the NRD (residues 21-41 in the zebrafish sequence, Figure 2A), 
cleaving the fusion linker, and uniformly deuterating the nonexchangeable hydrogen 
positions. We assigned 64% of the backbone HN, NH, Cα, and Cβ chemical shifts in this 
construct using triple-resonance backbone correlation spectra with TROSY readout.  Using 
TALOS-N (Shen and Bax 2015; Shen et al. 2009), we calculated the secondary structure 
index (SSI) and estimated backbone order parameter (RCI-S2, 0 is total disorder and 1 is fully 
rigid) for the assigned regions of both domains. We find significant structural order within a 
set of residues including sequences from both the NRD and TAD. Importantly, within this 
ordered region, the backbone chemical shifts for 71 out of 75 non-proline residues were 
assigned. Notably, the SSI analysis suggests that a stretch of residues in the TAD adopts a 
β-hairpin conformation, which contrasts the helical TAD structures typically observed in 
complexes with co-activator domains (De Guzman et al. 2006; Goto et al. 2002; Krois et al. 
2016; I. Radhakrishnan et al. 1997; Zor et al. 2004). 
To build a model of the core NRD-TAD structure, we prepared perdeuterated protein 
samples with isoleucine, leucine, and valine (ILV) methyl sidechain 13C/1H labels. We 
performed a combination of isotopomer-selective TOCSY experiments and several NOESY 
experiments to assign and validate the resonances of ILV methyls and generate a set of 
NOE-based distance restraints for structure calculations (see Methods) (Otten et al. 2010). 
We then combined the chemical shifts, NOE restraints, and RDCs to generate a set of 
structures using customized RASREC-Rosetta calculations, as described in Methods. We 
included only the core, structured sequences of each domain in the calculation. Sequences 
outside the core region are likely disordered, as suggested by no observable NOEs and low 
order parameters for assigned residues in the flanking regions. The structural ensemble of 
the NRD-TAD complex, which consists of ten top scoring models based on Rosetta energy 
function and good overall fit to the experimental data, showed high convergence with heavy 
atom root mean square displacements of 0.48Å for core residues. The observed backbone 
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conformation in these calculated models match TALOS-N chemical shift predictions of 
secondary structure and fits experimental RDC data well.  The core structured elements in 
the NRD and TAD correlate well with the sequences of highest conservation in those 
domains, and nearly all the residues that are key for forming the interface are conserved. 
The NRD-TAD structure consists of a five-stranded pleated β-sheet and a single α-
helix. Three of the beta strands (β1-β3) are from sequences in the NRD, and two additional 
strands are from sequences in the TAD (β4-β5). The amphipathic helix is an insertion 
between the parallel β2 and β3 strands in the NRD. One face of the helix packs against the 
β-sheet to form the hydrophobic core of the structure. Sidechains from β-strands in both the 
NRD (I64, V76, I78, F106, and L108, human sequence numbering) and TAD (L709 and 
L716) form an extended, buried interface through highly specific, experimentally confirmed 
interactions with helix residues (I84, I87, I88, and L91) (Figure 3A). The fact that both the 
NRD and TAD contribute essential residues to the hydrophobic core suggests the 
requirement of an association for forming the observed structure of both domains.  We 
explore this idea further below.  
The structured region of the TAD consists of a 12 amino acid sequence that adopts a 
β-hairpin conformation and binds the NRD by extending the β-sheet.  The NRD-TAD interface 
therefore consists of interstrand backbone hydrogen bonds between NRD β3 and TAD β4 
and several van der Waals contacts between sidechains in those β-strands and the NRD 
helix.  The backbone hydrogen-bonding network is supported by unambiguously assigned 
interstrand amide-amide NOE cross-peaks, and, likewise, the sidechain interactions are 
supported by methyl-methyl NOEs. Sidechain contacts at the interface are observed between 
I88, L91, F106, I107, and L108 in the NRD and L703, V708, L709, and L716 in the TAD.  
Interestingly, even when interacting with the NRD, ~20% of the TAD is structurally well 
defined, while the majority of the TAD remains intrinsically disordered. We propose that this 
small, structurally plastic region of the TAD is key for the regulation of FoxM1 activity. 
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Figure 3.3: Interactions stabilizing the NRD-TAD hydrophobic core and interface.   (A) 
Hydrophobic sidechains forming the structural core of the NRD-TAD complex. Human amino 
acid numbering is indicated.  Unambiguously assigned ILV methyl-methyl NOEs are shown 
as lines. (B) ITC measurements of the NRD-TAD binding affinity using the indicated WT or 
mutant domains. Mutations were chosen on the side of the β-sheet that is either proximal or 
distal to the α-helix.  (C) Luciferase reporter assays of FoxM1 transactivation activity. 
Reporter plasmids containing the luciferase gene downstream of either six repeats of a 
FoxM1 responsive element (6DB, left) or the PLK1 promoter sequence (PLK1p, right) were 
co-transfected with WT or mutant FoxM1 into U2OS cells. EV is empty vector. Significant 
differences in the relative luminescence from WT are indicated with asterisks: * p < 0.05, ** p 
< 0.01 (using two-tailed student’s t-test). 
 
3.2.3. The NRD-TAD has a hydrophobic core and disruption of the interface leads to 
heightened FoxM1 transcriptional activity  
 
 To probe the structural role of the NRD-TAD interface in repressing FoxM1 
transactivation, we first tested the effects of mutations in the NRD and TAD on the 
interdomain association using the ITC assay with human FoxM1 domains. For these 
experiments, we used the TAD (696-748) and a longer NRD (1-203), which were the most 
stable constructs containing each domain in solution and the simplest to purify. We 
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expressed and purified NRD constructs (residues 1-203) containing mutations in each of the 
three β-strands. These mutations, which replace hydrophobic sidechains for alanine, were 
made to residues on either the face of the β-sheet that interact with the helix (proximal) or the 
face pointing away from the helix (distal).  We find that mutations on the β-sheet face that is 
proximal to the helix all inhibit binding with the TAD (residues 696-748), with mutations on the 
two strands closest to the TAD (V76A/I78A in β2 and F106A/L108A in β3) having the greatest 
effects.  We find that mutations to the hydrophobic face of the NRD helix (I88A and L91A) 
also disrupt TAD binding. In contrast, mutations to the distal side of the NRD β-sheet only 
result in a modest decrease in affinity (I65A or V75A) or no change in affinity (I107A/I109A).  
We also substituted alanines for sidechains in the TAD near the NRD interface. We found 
that three mutations have strong effects on binding (V708A, L709A, L716A), while mutation at 
one sidechain that points toward the distal side of the sheet (M712A) has a modest effect. 
We next tested the effects of mutations to the NRD-TAD interface on FoxM1 activity in U2OS 
osteosarcoma cells using a luciferase reporter. We expressed WT and mutant FoxM1 
together with a plasmid that contains 6 tandem Forkhead-response elements (6DB) or the 
promoter of PLK1 (PLK1p), a FoxM1 target gene, upstream from the luciferase gene. As 
previously described, luciferase activity increases upon expression of WT FoxM1 compared 
to transfection of empty vector, which reflects the ability of FoxM1 to transactivate luciferase 
expression from the promoters in the reporter plasmid (Anders et al. 2011; Laoukili et al. 
2005).  We find that this activity is further increased upon expression of FoxM1 harboring 
mutations that destabilize the NRD-TAD interface. The cell reporter data generally correlate 
well with our in vitro ITC binding data.  For example, a β1 strand mutant (I62A/I64A), which 
only produces a modest loss of binding affinity, does not significantly change FoxM1 activity 
in the cell assay. In contrast, mutations closer to the interface in NRD strands β2 and β3, the 
NRD helix, and the TAD have strong effects. We conclude that the WT FoxM1 activity in this 
assay is mitigated by autorepression and that, by destabilizing the NRD-TAD structure and 
association, these mutations inhibit autorepression and result in higher activity. One 
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interesting exception to the observed correlation between the biochemical and cellular assays 
is the L716A mutation. This mutation results in complete loss of affinity but has a more 
modest activating effect in the luciferase assay compared to other TAD mutations.  We 
explore below an additional role for this residue in activation through recruitment of CBP/p300 
co-activator. 
 
3.2.4. Disruption of CBP binding motif decreases relief of repression 
 
  The structures of several TAD sequences bound to CBP or p300 KIX and TAZ2 
have been determined, and it is found that the intrinsically disordered TADs invariably adopt 
helical conformations when associated with co-activator (De Guzman et al. 2006; Goto et al. 
2002; Krois et al. 2016; I. Radhakrishnan et al. 1997; Goto et al. 2002).  Binding typically 
entails contacts from hydrophobic residues along the face of one or more short amphipathic 
helices in the TAD. Motifs such as ɸ-X-X-ɸ-ɸ or ɸ-ɸ-X-X-ɸ (ɸ is a bulky hydrophobic residue 
and X is any residue) are commonly observed in the TAD interacting sequences.  Two 
sequences in the FoxM1 TAD contain such a motif and appear amenable to forming 
amphipathic helices. We find that both of these sequences are required for TAZ2 binding. 
Notably, the predicted binding sequence around 713-726 overlaps with the sequence that 
forms the β-hairpin in binding the NRD in the repressed conformation.  We tested a L716A 
TAD mutant and found no detectable binding to TAZ2. The importance of L716 for CBP 
association explains how NRD binding inhibits CBP association and likely explains why the 
L716A mutation did not result in similar increased FoxM1 activity in the luciferase assay as 
other mutations in the TAD. The mutation disrupts both NRD inhibition and activation through 
CBP recruitment. 
 
3.2.5. FoxM1 TAD bound to CBP by NMR 
  
 To test the possibility of determining the secondary and/or tertiary structure of the 
TAD bound by CBP we used NMR and assigned the partial backbone of the FoxM1 TAD 
bound by CBP-TAZ2. We had previously sought to determine the backbone assignments and 
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subsequent secondary structure of the TAD bound by CBP-KIX (unpublished data), but due 
to tighter binding by TAZ2 we opted for structural analysis of the TAZ2 bound TAD. We were 
able to assign 64% of backbone residues, 55% of Cα atoms, and 45% of Cβ atoms (Table 
3.1). There is a substantial portion of the middle of the TAD that is entirely unassigned and is 
not visible by the 3D NMR acquisition parameters, specifically zebrafish residues 597-605, 
which correspond to human 719-727, a highly conserved region that we propose has critical 
binding residues based on mechanistic conservation of hydrophobic binding of TADs to CBP 
(De Guzman et al. 2006; Goto et al. 2002; F. Wang et al. 2012).  
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Table 3.1: FoxM1 TAD bound by CBP-TAZ2 chemical shift assignments. The FoxM1 
TAD and all assignments are categorized by atom type; H, amide proton, N, backbone 
nitrogen, Cα and Cβ carbon atoms. Values are in ppm in the respective dimension.  
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Figure 3.4: The FoxM1 TAD and CBP by NMR. (A) HSQC of 15N Dr FoxM1 TAD at 100 µM 
is titrated with molar equivalents of unlabeled TAZ2 as indicated by the key. While many 
residues are visible by HSQC, a significant number fall into intermediate exchange and 
additional residues are not visible in 3D data. (B) Binding analysis of two representative fast 
exchange residues in the bound HSQC show a plateau of chemical shift perturbation at a 2M 
equivalent of TAZ2:TAD. 
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 We first determined the ratio at which the FoxM1 TAD is saturated with TAZ2. To do 
this we titrated unlabeled TAZ2 into 100 µM 15N labeled TAD and graphed peaks in fast 
exchange. We found that at a 2M equivalent of TAZ2 (200 µM) to TAD we saw a plateau of 
chemical shift perturbation of residues in fast exchange, indicating that the TAD is saturated 
at 2M excess (Figure 3.4B). Consequently, all experiments moving forward were conducted 
at 2M excess of TAZ2 to FoxM1 TAD. Due to protein degradation and intermediate exchange 
we were unable to assign sufficient residues for 3D structure determination. There is a native 
linker fusion construct of TAZ2-TAD with an N terminal GST tag that expresses and could be 
tested for stability and signal (3.4 materials and methods).  
 
3.2.6. The FoxM1 TAD has α-helical propensity in a CBP bound state 
 
 The FoxM1 TAD binds to CBP TAZ2 and is partially visible by NMR in a bound state. 
Transcription factors that bind to CBP domains often adopt α-helical structure upon binding 
through a conserved hydrophobic interaction. Due to the conservation of both amino acid 
sequence in these hydrophobic sequences and conservation of mechanism we also expect 
the FoxM1 TAD to adopt helical propensity (Figure 3.5B). In addition, there are residues in 
the bound HSQC that perturb upfield in the 1H dimension, indicative of α-helical structure 
formation (Figure 3.5A). The FoxM1 TAD with the TEV linker site has 54 non-proline 
residues. In the bound HSQC we see 48 peaks and it is expected that some of these peaks 
are due to protein degradation over time. Though overall the bound state seems to remain 
primarily disordered, an interesting region of the FoxM1 TAD moves upfield in a manner that 
is indicative of α-helical propensity. 
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Figure 3.5: CBP bound TAD shows α-helical propensity. (A) NMR HSQC spectra show the 
unbound FoxM1 TAD (dark purple) overlaid with the bound FoxM1 TAD (light pink). Notably, 
we see chemical shift perturbations in the proton dimension moving upfield upon TAZ2 
interaction. (B) TADs typically adopt α-helical confirmations upon binding to TAZ2. Shown here 
are representative structures of TAD bound TAZ2 domain; top, TAZ2 bound by p53 (PDB ID 
5HPD), bottom, TAZ2 bound by E1A (PDB ID 2KJE). (C) TALON-N was used to predict 
secondary structure. Residue number on the x-axis corresponds to zebrafish FoxM1 TAD and 
secondary structure predictions are colors; α-helix orange, β-sheet blue, disorder gray.  
 To begin to ask questions regarding secondary structure during TAZ2 bound state of 
the FoxM1 TAD we assigned the protein amide backbone using triple resonance 
experiments. Of the available 48 of 54 peaks visible to assign 31 are assigned (64% 
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assigned residues). TALOS-N was used to predict secondary structure based of the TAZ2 
bound TAD based on chemical shifts as perturbed from random coil (Figure 3.5C). The 
FoxM1 TAD in a TAZ2 bound state has regions where the TAD tends to have an equal if not 
slightly larger probability of being in an α-helical state, specifically residues 587 – 593 and 
614 – 621. It is worth noting that one of the regions of the TAD that corresponds to the 
hydrophobic binding motif that commonly binds CBP regions is not visible by 3D NMR in the 
bound state and therefore could not be assigned nor predicted. While this extremely limits our 
investigation, we still believe based on the overall data that the FoxM1 TAD likely samples an 
α-helical state. This will be extended upon in the discussion. 
3.2.7. FoxM1 TAD is unstructured in a phosphorylated state 
 
 To further probe the structure of the TAD alone and the effects of Plk1 
phosphorylation, we collected NMR data and assigned the backbone amide chemical shifts 
for the zebrafish FoxM1 TAD (residues 571-623, which corresponds to human 696-748), 
using both unphosphorylated and Plk1-phosphorylated samples. 47 out of 50 of the non-Pro 
residues in the TAD and phosphorylated TAD were assigned. Using TALOS-N as above, we 
calculated the RCI-S2 order parameter for residues in both the phosphorylated and 
unphosphorylated TAD. The data support the conclusion that both the phosphorylated and 
unphosphorylated isolated TAD are primarily unstructured. These results in comparison with 
the NMR data for the NRD-TAD complex suggest that the β-hairpin structure of the TAD is 
adopted upon binding to the NRD. 
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Figure 3.6: The Plk1 phosphorylated TAD is intrinsically disordered. (A, B) CD spectra of 
the indicated purified proteins. (C) 2D 1H-15N HSQC spectra of the zebrafish FoxM1 TAD 
(corresponding to residues 696-748 in the human protein) either unphosphorylated (pink) or 
phosphorylated (green) recorded at 25°C at 800 MHz. Sequence specific assignments 
(examples shown for three Plk1-phosphorylated serines) were made using backbone triple 
resonance correlation spectra. (D) RCI-S2 order parameter plot of assigned residues in the free 
TAD and Plk1-phosphorylated TAD.  
 
3.2.8. Conclusions  
Detailed in Chapter 2 is the mechanism of FoxM1 activation and relief and 
repression in a phosphorylation dependent manner. Here in Chapter 3 we add onto the 
mechanism by detailing the core of the NRD-TAD association as well as the structural 
rearrangements in the TAD. These structural rearrangements occur in a phosphorylation 
dependent manner with the phosphorylation of S715 relieving the NRD sequestration of the 
TAD and allowing CBP to bind. This data was detailed in Chapter 2, Figure 2.5. Here we 
show that FoxM1 TAD has a hydrophobic core that can be destabilized by mutations and that 
these destabilizing mutations lead to increased FoxM1 transcriptional activity as monitored by 
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luciferase activity (Figure 3.3). This indicates to us that the hydrophobic core has a prominent 
role in the maintenance of the NRD-TAD association and subsequently the transcriptional 
activity of FoxM1. In addition to discovering the NRD-TAD core, we show that FoxM1 
undergoes significant structural rearrangements when transitioning from the repressed state 
to the active CBP bound state. Of note, we show the NRD and TAD to be both intrinsically 
disordered in isolation, but upon binding form structure (Figure 3.1, Figure 3.2). The TAD 
exhibits a β-sheet structure when bound by NRD, intrinsic disorder in isolation regardless of 
phosphorylation status, and has α-helical propensity when bound by CBP (Figure 3.5, Figure 
3.6). These findings compliment the work of Chapter 2 and progress our knowledge of cell 
cycle regulation, the structural dynamics of eukaryotic transcription factors, and FoxM1 
biology.  
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3.3 Discussion 
Eukaryotic transcription factors almost invariably contain large regions of intrinsic 
structural disorder, which facilitate protein-protein interactions for gene activation, 
posttranslational modifications for regulation, and control over nuclear localization (Minezaki 
et al. 2006; Wright and Dyson 2015).  Whereas structural disorder is required for function, it 
follows that the induction of structure could be used to negatively regulate transcription factor 
activity by restricting accessibility, particularly of the transactivation domain.  Indeed, our 
results show that the NRD of FoxM1 is able to bind the TAD and induce a structured 
conformation that is incompatible with its binding to co-activator protein. Interestingly, the 
repressed TAD has a β-hairpin structure, while the CBP bound state likely contains α-helical 
structures and involves a TAD sequence near the S715 phosphorylation site that overlaps 
with the NRD-binding sequence. Thus, FoxM1 regulation entails secondary structure 
switching of the TAD between strand, coil, and helical structures.  
We find that S715 phosphorylation destabilizes the NRD-TAD association and that 
the dissociated TAD is intrinsically disordered and capable of binding CBP. Phosphorylation 
has been observed to control structural transitions as a means to regulate other intrinsically 
disordered proteins. For example, both the transcription factor Ets-1 and the translation 
regulator 4E-BP2 undergo disorder-to-order transitions upon phosphorylation, while the 
nucleophosmin protein dissociates from a structured pentamer to a disordered monomer 
upon phosphorylation (Bah et al. 2015; Mitrea et al. 2014). FoxM1 demonstrates a new 
example in which the order-to-disorder transition occurs coincident with modulation of an 
intramolecular association between domains. This plasticity of disordered domains and the 
ability to regulate the plasticity through posttranslational modifications explains why 
intrinsically disordered proteins are so well suited to regulate biological function. 
Unexpectedly, our data indicate that in the active FoxM1 conformation, in which 
phosphorylation inhibits the repressive NRD-TAD association, the NRD is largely disordered 
as well as the TAD.  We propose that this additional disorder may be important to increase 
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conformational flexibility within the context of chromatin, to promote regulation of FoxM1 
stability, or to contribute to the formation of low complexity domain condensates as recently 
described (Chong et al. 2018; Laoukili et al. 2008; Liu et al. 2006; Minezaki et al. 2006; Park, 
Costa, et al. 2008; X. Wang et al. 2017; Wright and Dyson 2015). While several transcription 
factor NRDs have been characterized (W. Y. Kim et al. 1999; Park, Wang, et al. 2008; 
Ramsay and Gonda 2008; Shi, Kroeger, and Morimoto 1995; Spengler and Brattain 2006; 
Wierstra and Alves 2006), the idea that NRDs may appear in regions of intrinsic disorder 
should motivate the identification of additional “hidden” NRDs that adopt structure only upon 
interaction with their target. 
Like many cell division regulatory proteins, FoxM1 undergoes cell-cycle dependent 
multisite phosphorylation. While multiple Cdk and Plk1 phosphorylation events have been 
implicated in FoxM1 activation, our results demonstrate that phosphorylation of one specific 
Plk1 site (S715) is directly responsible for freeing the TAD from sequestration by the NRD. 
This result clarifies an indirect role for Cdk in driving FoxM1 activity through priming the CSR 
for Plk1 docking and further phosphorylation of the TAD (Fu et al. 2008). The idea that 
different phosphorylation events have specific and distinct roles is in contrast to several 
proposed models for multisite phosphorylation in the cell cycle, in which a threshold 
aggregate of redundant phosphorylation events drives a change in protein activity (Harvey et 
al. 2005; S. Y. Kim and Ferrell 2007). Our observation of specificity in the effects of FoxM1 
phosphorylation more resembles what has been proposed for the retinoblastoma protein, in 
which specific phosphorylation events drive distinct structural changes or protein-protein 
interactions (Rubin 2013).  
The structural picture revealed here of FoxM1 repression provides novel mechanistic 
insights into transcription factor regulation and may motivate novel cancer therapeutics.  It 
has been concluded that FoxM1 inhibition would significantly impact our treatment of several 
cancers that express high levels of the protein (Koo et al., 2012; Myatt and Lam, 2007; 
Raychaudhuri and Park, 2011). However, consistent with the challenges of targeting 
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transcription factors with chemotherapeutics, only few reports have described potential 
candidate molecules (Gormally et al. 2014; S. K. Radhakrishnan et al. 2006).  The 
identification of a structured, repressed conformation suggests the possibility of developing 
molecules that bind and stabilize the repressive NRD-TAD association or target FoxM1 for 
degradation.  
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3.4 Materials and Methods 
Protein Expression  
 The zebrafish FoxM1 TAD fused to mouse CBP-TAZ2 with a native FoxM1 linker was 
expressed in and purified from E. coli as N-terminal GST fusion proteins with TEV cleavage 
sites. Cells were induced in mid-log phase with 1 mM IPTG, cells were grown for 3-4 hours at 
25 °C. Protein was purified from lysates with glutathione sepharose affinity chromatography. 
Fusion was then cleaved with TEV protease overnight against dialysis buffer (25 mM Tris 8, 
200 mM NaCl, 5 mM DTT, 10% glycerol v/v) and once again the next morning. Cleaved 
fusion was then passed over glutathione sepharoto remove free GST, concentrated, and run 
over Superdex-75 (GE Healthcare) into 20 mM HEPES pH 7.5, 150 mM NaCl, 5% glycerol.  
 
Circular dichroism 
Circular dichroism spectra of the FoxM1 proteins, prepared in 20 mM sodium 
phosphate and 50 mM NaCl buffer (pH 7.0), were measured on a JASCO J-1500 
spectrometer using a 1 mm path length quartz cuvette. Data were collected every 0.1 nm 
from 190 to 300 nm using a scanning speed of 50 nm/min, a digital integration time of 4 s, 
and a bandwidth of 4 nm. Eight sets of data were collected for each protein. Protein 
concentrations ranged from 35 µM to 10 µM and were measured using absorption at 280 nM. 
 
Protein expression for NMR 
Zebrafish FoxM1 (DrFoxM1) transactivation domain (G571-K623) and NRD-TAD 
fusion (Figure 2-figure supplement 1A) were expressed and purified from E. coli as above 
except the cells were grown in M9 medium supplemented with 15N ammonium chloride and 
13C glucose. For isoleucine, leucine, and valine specific isotope labeling the cells were grown 
as above in deuterated M9 medium supplemented with deuterated 12C glucose and the 
specific precursors added 30 minutes before induction as described (Tugarinov and Kay 
2003). For the isotopomer-selective TOCSY experiment, DrFoxM1 was grown in D2O M9-
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media using 13C glucose (1H,13C-glucose). For the ILV sample, residues L19, L104, C87, 
L569, V571, L622 were mutated to alanine to reduce the number of overlapped peaks in the 
methyl spectra and to prevent disulfide formation. For each NMR sample, the protein was 
purified as described in Chapter 2 and cleavage of the TEV linker was monitored by SDS-
PAGE.  
 
Nuclear magnetic resonance data collection and assignments  
FoxM1 NRD-TAD fusion 
NMR experiments for resonance assignment were performed on a Bruker Avance III 
HD 800-MHz spectrometer equipped with a cryogenically cooled probe head.  All samples 
were prepared in a buffer containing 20 mM sodium phosphate pH 6.3, 100 mM KCl, and 5% 
(v/v) D2O. The NMR spectra for backbone resonances assignments were collected using a 
270 μM uniformly 13C, 15N–labeled deuterated DrFoxM1 NRD-TAD. Sequence-specific 
backbone resonance assignments for DrFoxM1 NRD-TAD were determined using all 
TROSY-HSQC, TROSY-HNCO, TROSY-HN(CA)CO, TROSY-HNCA, TROSY-HN(CO)CA, 
TROSY-HNCB, and TROSY-HN(COCA)CB experiment supplied by Bruker BioSpin. NMR 
spectra for methyl sidechain assignments were collected using 270 μM deuterated uniformly 
15N-labeled, methyl site specific 13C-labeled protein. Methyl sidechain assignments were 
determined using an isotopomer-selective TOCSY and SOFAST NOESY, HMQC, and 
methyl-HSQC experiments (Otten et al. 2010; Rossi et al. 2016). Data from the protein 
samples with methyl specific labels was collected using SOFAST pulse sequences (Rossi et 
al. 2016), including amide to amide NOESY (HN-NHN and N-NHN), amide to methyl (HNHAro-
CMHM and CM-NHN) and methyl to methyl (HM-CMHM and CM-CMHM) SOFAST NOESY 
experiments all recorded with a recycle delay of 0.2 sec and an NOE mixing time of 300 
msec.  
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FoxM1 TAD 
NMR experiments for resonance assignment were performed on a Bruker Avance III 
HD 800-MHz spectrometer equipped with a cryogenically cooled probe head.  All samples 
were prepared in a buffer containing 20 mM Sodium Phosphate pH 6.3, 100 mM KCl, and 5% 
(v/v) D2O. The NMR spectra for backbone resonances assignments were collected using a 
450 μM uniformly 13C, 15N–labeled DrFoxM1 TAD protein. NMR labeled TAD protein was 
phosphorylated by Plk1 kinase domain as described above. Sequence-specific backbone 
resonance assignments for DrFoxM1 TAD were determined using HSQC, HNCO, HNCACB, 
CBCA(CO)NH, and C(CO)NH experiment supplied by Bruker BioSpin. Sequence-specific 
backbone resonance assignments for phosphorylated DrFoxM1 TAD were determined using 
HSQC, HNCO, HNCACB, and CBCA(CO)NH experiments supplied by Bruker BioSpin.  
 
FoxM1 TAD-TAZ2 
NMR experiments for resonance assignment were performed on a Bruker Avance III 
HD 800-MHz spectrometer equipped with a cryogenically cooled probe head.  All samples 
were prepared in a buffer containing 20 mM Sodium Phosphate pH 6.3, 100 mM KCl, and 5% 
(v/v) D2O. The NMR spectra for backbone resonances assignments were collected using a 
1μM uniformly 13C, 15N–labeled DrFoxM1 TAD protein and incubated with 2M excess 
unlabeled TAZ2. Sequence-specific backbone resonance assignments for DrFoxM1 TAD-
TAZ2 were determined using HSQC, HNCO, HNCACB, CBCA(CO)NH, and C(CO)NH, 
HBHA(CO)NH experiment supplied by Bruker BioSpin.  
 
Residual Dipolar Coupling 
The backbone DNH (NH) dipolar couplings used for RASREC-Rosetta structure 
modeling were measured using uniformly 15N-labeled deuterated FoxM1 NRD-TAD protein. 
The NMR sample was made by mixing DrFoxM1 NRD-TAD (250 µM final concentration) with 
Pf1 phage (12.5 mg/mL final concentration) and 10% D2O (Hansen et al., 1998).  RDCs were 
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collected on a Varian INOVA 600 MHz spectrometer using J modulation experiments similar 
to those described (Tjandra et al., 1996). The DNH coupling experiment was performed with 
the ILV NRD-TAD sample containing the alanine mutations (Figure 2-figure supplement 1A). 
A separate set of backbone DNC’ (NCO) dipolar couplings were measured using uniformly 
15N/13C/2D labeled FoxM1 NRD-TAD fusion protein and used for structure validation.  This set 
of RDCs were not used in the structural calculation of the FoxM1 model.  The NMR sample 
was made by mixing DrFoxM1 NRD-TAD (250 µM final concentration) with Pf1 phage (12.5 
mg/mL final concentration) and 10% D2O (Hansen et al., 1998).  RDCs were collected on a 
Varian INOVA 600 MHz spectrometer using J modulation experiments similar those 
described previously (Liu and Prestegard, 2010). The DNC’ coupling experiment was 
performed with the uniformly 15N/2D-labeled NRD-TAD fusion sample (no alanine mutations) 
used for backbone assignments. 
All NMR data were processed with NMRPipe and NMRDraw (Delaglio et al. 1995). 
Chemical-shift assignments were made with SPARKY 
(https://www.cgl.ucsf.edu/home/sparky/).  
 
Structure modeling using RASREC-Rosetta 
Structural models of the NRD-TAD complex were calculated using RASREC-Rosetta 
(Nerli and Sgourakis 2019). RASREC-Rosetta is a Monte Carlo-based fragment assembly 
approach that utilizes NMR chemical shifts to guide the conformation search for a near-native 
structure. Together with NMR chemical shifts, which aid in the selection of accurate 
secondary structural elements, we utilized NOE and RDC measurements that helped identify 
the correct fold of the two domain(Tyka et al. 2011). Alongside NMR data, RASREC-Rosetta 
uses optimized algorithms across six stages of resampling in a parallelized manner to 
achieve high structural convergence. During the initial stages of the protocol, various -sheet 
topologies are sampled. In the subsequent stages, fragments derived from (i) high-resolution 
X-ray structures, and (ii) preliminary low-resolution conformations (from the initial sampling 
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stages), are applied to intensify and finalize the folds of a target protein. In the final stages of 
the protocol, the low-resolution models generated during the initial and intermediate stages 
are refined in the Rosetta force field to produce high-resolution structures. 
Structure calculations were set up with automated Python scripts available at the CS-
Rosetta website (https://csrosetta.chemistry.ucsc.edu). Prior to setting up these calculations, 
we (i) removed flexible end regions in the target sequence based on TALOS-N RCI-S2 
predictions, and (ii) used the trimmed target sequence and chemical shift values to pick 
structural fragments of amino acid lengths 3 and 9 (standard lengths). After these steps, we 
used the protein sequence, structural fragments, chemical shift, NOE and RDC 
measurements as input to the RASREC-Rosetta protocol. From a set of 100 models 
generated by RASREC-Rosetta in its final stage, we selected 30 lowest energy models from 
which, we filtered ten converged structures that fit the experimental RDC data. We 
subsequently refined the final ensemble twice (first, using NOE and RDC data sets and 
second, without any data sets to eliminate heavy bias from NMR data) using Rosetta’s relax 
protocol (Tyka et al. 2011). The structures of NRD-TAD domains were calculated by treating 
the protein as a single polypeptide chain with the TEV site as a linker, which was later 
removed from the models. 
To calculate the structural models of the FoxM1 NRD-TAD domains, we used a total 
of 64 NOE distance restraints derived from highly sensitive SOFAST-based experiments 
recoded with short inter scan delays (200 msec) and long (300 msec) mixing times. These 
distance restraints consist of (i) 14 amide to amide, (ii) 11 amide to methyl, and (iii) 39 methyl 
to methyl NOEs. The observed intensities of the NOEs can be affected by distance-
independent processes such as T1 relaxation and spin diffusion during the long NOE mixing 
time. Accordingly, we considered several additional parameters, alongside the signal 
intensities of the NOEs (relative to their diagonals), to calibrate upper distance bounds for all 
the three classes of NOE restraints described above. In particular, we performed an analysis 
of distance statistics within -sheet structures in the PDB and used preliminary models of the 
 60 
 
NRD-TAD domains calculated using more generous (7 Å), uniform NOE distance limits as 
benchmarks. First, we filtered NOEs based on high signal intensities. From a non-redundant 
set of 5 -sheet X-ray structures in PDB, we found that anti-parallel -strands have NOEs 
between pairs of amide protons within 3 Å or 5 Å and parallel -strands within 3 Å or 4 
Å. We then used the approximate relation that, NOE signal intensities are inversely 
proportional to sixth power of distances (𝐼𝑁𝑂𝐸 = 𝑐 × 𝑟
−6, where 𝐼𝑁𝑂𝐸  is the NOE signal 
intensity, 𝑐 is the proportionality constant and 𝑟 is the distance), to obtain estimates of upper 
distance bounds. To determine the proportionality constant, we used the strongest-intensity 
NOE and approximate distances between the amide protons from -sheet X-ray structures in 
PDB. Further, we applied the estimated proportionality constant and measured signal 
intensities to generate upper distance bounds for other amide-amide NOEs. Similarly, we 
used preliminary models computed using fixed distance bounds to calibrate distances of 
amide-methyl and methyl-methyl NOEs. Using this process, we observed that the resulting 
convergence of NRD-TAD ensemble calculated by RASREC-Rosetta increased 
progressively, together with the optimization of structural quality parameters such as Rosetta 
energies and MOLPROBITY scores.  
 
Cell culture  
Human osteosarcoma U2OS cells were maintained in Dulbecco’s modiﬁed Eagle’s 
medium (DMEM) containing 10% fetal bovine serum, 2mM L-glutamine, and 1x Penicillin 
Streptomycin and split every 2-3 days. Cells tested negative for Mycoplasma contamination 
using a PCR assay. 
Reporter assays were performed using the FoxM1c isoform, which includes 15 amino 
acids downstream of the DNA binding domain that are absent in FoxM1b. The amino acid 
sequence of the NRD, CSR and TAD domains are identical in FoxM1c and FoxM1b. For 
clarity, mutations are indicated using FoxM1b numbering throughout the figures and text. 
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Mutants were expressed from the pCDNA3 plasmid with and contain an N-terminal FLAG 
tag: pCDNA3-FOXM1C (WT), pCDNA3-FOXM1C-I62A I64A, pCDNA3-FOXM1C-V76A I78A, 
pCDNA3-FOXM1C-I88A, pCDNA3-FOXM1C-I88A L91A T92A, pCDNA3-FOXM1C-F106A 
L108A, pCDNA3-FOXM1C-V723A (V708A in FOXM1b), pCDNA3-FOXM1C-L724A (L709A in 
FOXM1b), pCDNA3-FOXM1C-V723A L724A (V708A L709A in FOXM1b), pCDNA3-
FOXM1C-L731A (L716A in FOXM1b), pCDNA3-FOXM1C-S730A (S715A in FOXM1b).  In 
co-expression experiments with Plk1, Plk1 was expressed from pRcCMV myc-Plk1 wt (a gift 
from Erich Nigg) (Golsteyn et al., n.d.). The day prior to transient transfections, 2x105 U2OS 
cells were seeded into 12-well plates in antibiotic-free medium (DMEM/ 10%FBS/L-
glutamine). Cells were then transfected with Lipofectamine 2000 Reagent (Invitrogen 11668-
019) according to the manufacturer’s protocol with 650ng pGL3-6DB-reporter or pGL3-PLK1 
promoter reporters (a kind gift from Piotr Sicinski, (Anders et al. 2011)), 650ng pcDNA3-
FOXM1C (WT or mutant), and 10ng of pCMV-Renilla luciferase. In experiments that assayed 
activation by Plk1, 160ng of pRcCMV myc-Plk1 wt or an empty vector control also included. 
Media was refreshed 4 hours post-transfection. Cell lysates were prepared 25 hours post-
transfection using the Promega Dual Luciferase Reporter Assay System kit (Promega, 
E1960) and luminescence was measured on a Promega Glo Max. Relative luminescence 
was determined by normalizing the Firefly luciferase activity (expressed by pGL3 reporter 
plasmids) activity to Renilla Luciferase (transfection efficiency control). Three technical 
replicate transfections were performed in each experiment and each experiment was carried 
out three times (biological replicates). Analysis was performed in Excel and GraphPad Prism 
software.   
 
Western blot and cell cycle analysis 
The day prior to transient transfections, 2x106 U2OS cells were seeded into 10cm 
plates in antibiotic-free medium (DMEM/ 10%FBS/L-glutamine). Cells were then transfected 
with Lipofectamine 2000 Reagent (Invitrogen 11668-019) according to the manufacturer’s 
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protocol with 9.5μg pcDNA3-FOXM1 plasmids. Media was refreshed 4 hours post-
transfection. Cell lysates were prepared 25 hours post-transfection by resuspending cells in 
RIPA buffer (150mM NaCl, 1% Triton-X 100, 0.5% Sodium deoxycholate, 0.1% SDS, 50mM 
Tris-Cl pH 8.0, 5mM Sodium Fluoride, 1mM Sodium Orthovanadate, 80mM β-
glycerophosphate, 1μg/mL Leupeptin, 1μg/mL bestatin, 1μM Benzamidine HCl, 1mM DTT) 
for 30 minutes on ice, followed by centrifugation. Protein concentration was determined using 
Bio-Rad Protein Assay Dye Reagent (Cat#5000006) and measured on an Eppendorf 
BioPhotometer Plus. Lysates were added to 4X SDS-PAGE Sample Buffer (0.25 M Tris pH 
6.8, 8% SDS, 40% glycerol, 20% β-mercaptoethanol) and heated to 95°C for 5 minutes. 10-
20μg total protein was then subjected to SDS–polyacrylamide gel electrophoresis (SDS–
PAGE), followed by transfer to nitrocellulose membranes, and Western blotting with the 
following antibodies: rabbit anti-FoxM1 (Bethyl A301-533A-M), mouse anti-actin (Sigma 
A1978), mouse anti-Flag (Sigma F1804). For cell cycle analysis, cells were fixed in 70% 
ethanol at 4˚C overnight. Cells were then centrifuged, washed with PBS, washed with PBS 
with 0.5% Tween20, then incubated with IFA 5μg/ml RNaseA for 30 minutes at 37˚C. 
Propidium iodide was added to a final concentration of 50μg/ml. Data were collected using a 
Guava EasyCyte HT (Millipore) and analyzed with FlowJo software.  
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